Fresenius Kabi is Doing More in America

Fresenius Kabi is a global health care leader that specializes in lifesaving medicines and technologies for infusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Here's how we are doing More in America.

More Leadership

A market leader¹ in injectable drugs and delivery systems to treat a wide range of patients in America.







Leading the way with smart RFID labeled medications.

More Confidence

Bringing more products to market that can help improve safety and efficiency for physicians, pharmacists, nurses and patients.



More Essential Medicines



Today, more than 70% of the units shipped by Fresenius Kabi in the U.S. are drugs listed on the FDA's Essential Medicines List.3



More Capacity

Nearly

spent to expand our U.S.-based production and distribution capabilities and capacities.

of our pharmaceuticals for the U.S. are proudly formulated, filled and packaged in the U.S.⁴



Backed by a global network of R&D centers and production facilities.



More Access

More than 700 SKUs in the Fresenius Kabi portfolio.4



More than 900 million units shipped over last 2 years in the U.S.5



More Oncology Options

60+

Unique oncology product codes, 12 products in market leading positions.6

12.000+

U.S. clinics and hospitals received Fresenius Kabi oncology products in 2023.7

A Commitment to Innovation

Growing and investing in the latest technologies and forward-thinking innovations to expand access and affordability.



Biosimilars

Expanding access to life-changing medicines through advanced science, manufacturing and support.



MedTech

Ivenix™ Infusion System is designed with safety in mind.8



Contrast Agents

Bringing contrast agents to market providing value, choice and flexibility.



Smart Labels

Supporting a safe, more efficient medication inventory process.

Fresenius Kabi is working shoulderto-shoulder with clinicians to build more confidence in the supply chain of care in America.



CARING) RE IN AMERICA



- IQVIA 9/30/22 MAT
- Data on file 5/1/24; calculation includes all ILEs approved in the U.S. During the first half of 2022, Data on file.; https://www.fda.gov/media/143406/download
- 2023 data on file
- 5 2022-2023 data on file
- 6 products at #1 market share and 6 products at #2 market share. Source: IQVIA 2023 data on file
- 8. Penover D. Guiliano K. Middleton A. BMJ Innov Epub ahead of print: 18April2022 doi:10.1136/bmjinnov-2021-000851. Compares Ivenix to a single competitor